콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

926027

Sigma-Aldrich

NanoFabTX-DOTAP Lipid Mix

for synthesis of cationic (DOTAP) liposomes

동의어(들):

Drug delivery, LNP, Microfluidics, NanoFab reagent kit, Nanoformulation, Nanoparticle

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12162002
NACRES:
NA.23

Quality Level

저장 온도

−20°C

일반 설명

NanoFabTx-DOTAP Lipid Mix includes reagents and optimized protocols with step-by-step instructions for synthesizing cationic liposomes for drug delivery research applications. The modification of liposomes with the cationic lipid, DOTAP, have numerous advantages such as their large-DNA incorporation, high transfection efficiency, and low toxicity. Liposome-based formulations are widely used for drug delivery applications and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins, and peptides.

Comprehensive protocols for liposome synthesis are included:

  • A lipid film hydration and extrusion protocol.
  • A microfluidics protocol using commercial platforms or syringe pumps.

The microfluidics protocol included with this product uses NanoFabTx device kits (911593). These kits come with the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

애플리케이션

NanoFabTx-DOTAP Lipid Mix is a ready-to-use nanoformulation blend for the synthesis of cationic DOTAP-functionalized liposomes. This kit enables users to encapsulate a wide variety of therapeutic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx kits provide an easy-to-use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

특징 및 장점

  • A ready-to-use nanoformulation blend for the synthesis of cationic liposomes
  • Step-by-step protocols (extrusion or microfluidic) developed and tested by our formulation scientists
  • Flexible synthesis tools to create uniform and reproducible liposomes
  • Optimized to make liposomes around 100 nm with low polydispersity
  • DOTAP surface-functionalized allows for targeting ligand conjugation to enable targeted drug delivery

법적 정보

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin VP, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin V P, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)
D Papahadjopoulos et al.
Proceedings of the National Academy of Sciences of the United States of America, 88(24), 11460-11464 (1991-12-15)
The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have a pronounced effect on liposome tissue distribution and can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs. This effect

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.